Multidrug resistance-associated protein 1 (
MRP1, encoded by the ABCC1 gene) may contribute to the clearance of
amyloid-beta (Aβ)
peptides from the brain into the blood and stimulation of
MRP1 transport activity may be a therapeutic approach to enhance brain Aβ clearance. In this study, we assessed the effect of
thiethylperazine, an
antiemetic drug which was shown to stimulate
MRP1 activity in vitro and to decrease Aβ load in a rapid β-
amyloidosis mouse model (APP/PS1-21), on
MRP1 transport activity by means of positron emission tomography (PET) imaging with the
MRP1 tracer 6-bromo-7-[11C]methylpurine. Groups of wild-type, APP/PS1-21 and Abcc1(-/-) mice underwent PET scans before and after a 5-day oral treatment period with
thiethylperazine (15 mg/kg, once daily). The elimination rate constant of radioactivity (kelim) was calculated from time-activity curves in the brain and the lungs as a measure of tissue
MRP1 activity. Treatment with
thiethylperazine had no significant effect on
MRP1 activity in the brain and the lungs of wild-type and APP/PS1-21 mice. This may either be related to a lack of an MRP1-stimulating effect of
thiethylperazine in vivo or to other factors, such as substrate-dependent
MRP1 stimulation, insufficient target tissue exposure to
thiethylperazine or limited sensitivity of the PET tracer to measure
MRP1 stimulation.